Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Myriad Genetics (MYGN) Interest Expenses (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Interest Expenses for 16 consecutive years, with $4.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Interest Expenses rose 528.57% to $4.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $10.5 million, a 275.0% increase, with the full-year FY2025 number at $10.5 million, up 275.0% from a year prior.
  • Interest Expenses was $4.4 million for Q4 2025 at Myriad Genetics, up from $3.8 million in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $4.4 million in Q4 2025 to a low of $500000.0 in Q4 2021.
  • A 5-year average of $1.3 million and a median of $850000.0 in 2022 define the central range for Interest Expenses.
  • Peak YoY movement for Interest Expenses: crashed 91.38% in 2021, then skyrocketed 528.57% in 2025.
  • Myriad Genetics' Interest Expenses stood at $500000.0 in 2021, then soared by 80.0% to $900000.0 in 2022, then changed by 0.0% to $900000.0 in 2023, then decreased by 22.22% to $700000.0 in 2024, then surged by 528.57% to $4.4 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Interest Expenses are $4.4 million (Q4 2025), $3.8 million (Q3 2025), and $1.5 million (Q2 2025).